Login to Your Account

Launches Pivotal Prostate Cancer Trial

Exelixis Submits Cabo NDA in Medullary Thyroid Cancer

By Marie Powers
Staff Writer

Thursday, May 31, 2012
Just in time for the American Society of Clinical Oncology (ASCO) meeting in Chicago, Exelixis Inc. completed the filing of its rolling new drug application (NDA) with the FDA for cabozantinib (XL184) in the lead indication of progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription